1
|
Chiang CJ, Chao YP, Ali A, Day CH, Ho TJ, Wang PN, Lin SC, Padma VV, Kuo WW, Huang CY. Probiotic Escherichia coli Nissle inhibits IL-6 and MAPK-mediated cardiac hypertrophy during STZ-induced diabetes in rats. Benef Microbes 2021; 12:283-293. [PMID: 34030609 DOI: 10.3920/bm2020.0094] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Escherichia coli Nissle (EcN), a probiotic bacterium protects against several disorders. Multiple reports have studied the pathways involved in cardiac hypertrophy. However, the effects of probiotic EcN against diabetes-induced cardiac hypertrophy remain to be understood. We administered five weeks old Wistar male (271±19.4 g body weight) streptozotocin-induced diabetic rats with 109 cfu of EcN via oral gavage every day for 24 days followed by subjecting the rats to echocardiography to analyse the cardiac parameters. Overexpressed interleukin (IL)-6 induced the MEK5/ERK5, JAK2/STAT3, and MAPK signalling cascades in streptozotocin-induced diabetic rats. Further, the upregulation of calcineurin, NFATc3, and p-GATA4 led to the elevation of hypertrophy markers, such as atrial and B-type natriuretic peptides. In contrast, diabetic rats supplemented with probiotic EcN exhibited significant downregulated IL-6. Moreover, the MEK5/ERK5 and JAK2/STAT3 cascades involved during eccentric hypertrophy and MAPK signalling, including phosphorylated MEK, ERK, JNK, and p-38, were significantly attenuated in diabetic rats after supplementation of EcN. Western blotting and immunofluorescence revealed the significant downregulation of NFATc3 and downstream mediators, thereby resulting in the impairment of cardiac hypertrophy. Taken together, the findings demonstrate that supplementing probiotic EcN has the potential to show cardioprotective effects by inhibiting diabetes-induced cardiomyopathies.
Collapse
Affiliation(s)
- C J Chiang
- Department of Medical Laboratory Science and Biotechnology, China Medical University, 91 Hsueh-Shih Rd., Taichung 40402, Taiwan
| | - Y P Chao
- Department of Chemical Engineering, Feng Chia University, No. 100 Wenhwa Rd., Seatwen, Taichung 40724, Taiwan
| | - A Ali
- Department of Biological Science and Technology, China Medical University, 91 Hsueh-Shih Rd., Taichung 40402, Taiwan
| | - C H Day
- Department of Nursing, MeiHo University, 23, Pingguang Rd., Neipu, Pingtung 912, Taiwan
| | - T J Ho
- Department of Chinese Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Tzu Chi University, 707 Section 3 Chung-Yang Road, Hualien 97002, Taiwan.,Integration Center of Traditional Chinese and Modern Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien 97002, Taiwan.,School of Post-Baccalaureate Chinese Medicine, College of Medicine, Tzu Chi University, 701 Jhongyang Road Section 3, Hualien 97004, Taiwan
| | - P N Wang
- Department of Chemical Engineering, Feng Chia University, No. 100 Wenhwa Rd., Seatwen, Taichung 40724, Taiwan
| | - S C Lin
- Department of Medical Laboratory Science and Biotechnology, China Medical University, 91 Hsueh-Shih Rd., Taichung 40402, Taiwan
| | - V V Padma
- Department of Biotechnology, Bharathiar University, Coimbatore, India
| | - W W Kuo
- Department of Biological Science and Technology, China Medical University, 91 Hsueh-Shih Rd., Taichung 40402, Taiwan.,Ph.D. Program for Biotechnology Industry, China Medical University, Taichung 406, Taiwan
| | - C Y Huang
- Cardiovascular and Mitochondrial Related Disease Research Center, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien 97002, Taiwan.,Graduate Institute of Biomedical Sciences, China Medical University, Taichung 404, Taiwan.,Department of Medical Research, China Medical University Hospital, China Medical University, 91 Hsueh-Shih Rd., Taichung 40402, Taiwan.,Department of Biotechnology, Asia University, 500 Liufeng Rd., Wufeng, 41354 Taichung, Taiwan.,Center of General Education, Buddhist Tzu Chi Medical Foundation, Tzu Chi University of Science and Technology, Hualien 970, Taiwan
| |
Collapse
|
2
|
Huang CY, Velmurugan BK, Chen MC, Day CH, Chien WS, Padma VV, Wu HC, Lin TH, Hsu HH, Shen CH. KHC-4 inhibits β-catenin expression in prostate cancer cells. Biotech Histochem 2019; 94:374-380. [PMID: 30819007 DOI: 10.1080/10520295.2019.1574026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
Abstract
KHC-4 is a 2-phenyl-4-quinolone analogue that exhibits anticancer activity. Aberrant activation of β-catenin signaling contributes to prostate cancer development and progression. Therefore, targeting β-catenin expression could be a useful approach to treating prostate cancer. We found that KHC-4 can inhibit β-catenin expression and its signaling pathway in DU145 prostate cancer cells. Treatment with KHC-4 decreased total β-catenin expression and concomitantly decreased β-catenin levels in both the cytoplasm and nucleus of cells. KHC-4 treatment also inhibited β-catenin expression and that of its target proteins, PI3K, AKT, GSK3β and TBX3. We monitored the stability of β-catenin with the proteasomal inhibitor, MG132, in DU145 cells and found that MG132 reversed KHC-4-induced proteasomal β-catenin degradation. We verified CDK1/β-catenin expression in KHC-4 treated DU145 cells. We found that roscovitine treatment reversed cell proliferation by arresting the cell cycle at the G2/M phase and β-catenin expression caused by KHC-4 treatment. We suggest that KHC-4 inhibits β-catenin signaling in DU145 prostate cancer cells.
Collapse
Affiliation(s)
- C-Y Huang
- a Graduate Institute of Basic Medical Science, China Medical University , Taichung , Taiwan.,b Graduate Institute of Chinese Medical Science, China Medical University , Taichung , Taiwan.,c Department of Health and Nutrition Biotechnology, Asia University , Taichung , Taiwan.,d Medical Research Center for Exosomes and Mitochondria Related Diseases, China Medical University Hospital , Taichung , Taiwan
| | - B K Velmurugan
- e Toxicology and Biomedicine Research group, Faculty of Applied Sciences, Ton Duc Thang University , Ho Chi Minh City , Vietnam
| | - M-C Chen
- f Division of Colorectal Surgery, Department of Surgery, Taichung Veterans General Hospital , Taichung , Taiwan
| | - C H Day
- g Department of Nursing, MeiHo University , Pingtung , Taiwan
| | - W-S Chien
- a Graduate Institute of Basic Medical Science, China Medical University , Taichung , Taiwan
| | - V V Padma
- h Department of Biotechnology, Bharathiar University , Coimbatore , India
| | - H-C Wu
- i School of medicine, China Medical University , Taichung , Taiwan
| | - T-H Lin
- j Division of Urology, Buddhist Tzu-Chi General Hospital , Taichung , Taiwan
| | - H-H Hsu
- k Division of Colorectal Surgery, Mackay Memorial Hospital , Taipei , Taiwan
| | - C-H Shen
- c Department of Health and Nutrition Biotechnology, Asia University , Taichung , Taiwan.,l Ditmanson Medical Foundation, Chia-Yi Christian Hospital , Chiayi City , Taiwan
| |
Collapse
|